医療関係者様へ

2023年発表論文

2023.02.06

2023年に当教室で発表した和文論文です。

題名（論文名）	著者	掲載雑誌
【女性に限らないHPV関連癌について知ろう!～子宮頸癌以外のHPV関連癌】尿路性器癌とHPV感染．	川口昌平、重原一慶、溝上敦．	日本性感染症学会誌2023; 33(1): 7-11.
75歳以上の高齢者に対する前立腺癌スクリーニング戦略の検討．	岩本大旭, 門本卓, 八重樫洋, 川口昌平, 野原隆弘, 重原一慶, 泉浩二, 角野佳史, 溝上敦．	日本腎泌尿器疾患予防医学研究会誌2023; 31(1): 41-43.
BEP療法におけるpegfilgrastim併用の安全性についての検討．	中川竜之介, 岩本大旭, 内藤伶奈人, 門本卓, 八重樫洋, 川口昌平, 野原隆弘, 重原一慶, 泉浩二, 角野佳史, 溝上敦．	日本腎泌尿器疾患予防医学研究会誌2023; 31(1): 56-58.
機能廃絶移植腎に発生した腎癌に対して移植腎摘除術を施行した1例．	門本卓, 鳥海蓮, 牧野友幸, 内藤伶奈人, 岩本大旭, 八重樫洋, 川口昌平, 重原一慶, 野原隆弘, 泉浩二, 溝上敦．	日本臨床腎移植学会雑誌2023; 11(2): 156-159
【臨床前立腺癌学-基礎・臨床の最新知見-】基礎研究　発癌・進展機序の解明　前立腺癌再燃時の副腎性アンドロゲンの役割．	溝上敦．	日本臨床2023; 81(増刊6 臨床前立腺癌学): 23-29.
免疫チェックポイント阻害薬の使い方&irAE対策】泌尿器がん．	泉浩二	薬事　2023; 65(6): 1117-1122.

2023年に当教室の医局員がfirst authorで発表した英文論文です

題名（論文名）	著者	掲載雑誌
Editorial Comment to Omitting routine cystography after RARP: Analysis of complications and readmission rates in suprapubic and transurethral drained patients.	Iwamoto H, Izumi K, Mizokami A.	Int J Urol. 2023: 30(2):218-219
Are bladder washing samples suitable for investigation of HPV infection in urinary bladder? Comparison in HPV prevalence between urine and washing samples.	Nakagawa T, Shigehara K, Kato Y, Kawaguchi S, Nakata H, Nakano T, Izumi K, Kadono Y, Mizokami A	J Med Virol. 2023; 95(1):e28110.
Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic.	Toriumi R, Yaegashi H, Kadomoto S, Iwamoto H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A.	Cancer Sci. 2023; 114(1):201-210.
Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival.	Nakagawa R, Nohara T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Shigehara K, Izumi K, Kadono Y, Mizokami A.	Photodiagnosis Photodyn Ther. 2023; 42:103574.
Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?	Nakagawa R, Iwamoto H, Naito R, Kadomoto S, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A.	Anticancer Res. 2023;43(3):1351-1359.
Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20-CCR6 axis.	Kano H, Izumi K, Hiratsuka K, Toriumi R, Nakagawa R, Aoyama S, Kamijima T, Shimada T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Kadono Y, Saito Y, Nakagawa-Goto K, Yoshioka K, Nakata H, Lin WJ, Mizokami A.	Cancer Sci. 2023; 114(4):1479-1490.
Comparison of postoperative urinary continence and incontinence types between conventional and Retzius-sparing robot-assisted radical prostatectomy.	Kadono Y, Nohara T, Kawaguchi S, Makino T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Shigehara K, Izumi K, Mizokami A.	Neurourol Urodyn. 2023; 42(6):1411-1420.
Efficacy of keishibukuryogan for hot flashes in prostate cancer patients receiving androgen deprivation therapy; A sub-analysis focusing on hormonal and cytokine levels.	Shigehara K, Izumi K, Nakashima K, Kawaguchi S, Nohara T, Kadono Y, Mizokami A.	Transl Urol Androl 2023; 12(8):1273-1282.
Postoperative functional and cancer control evaluation of conventional and Retzius-sparing robot-assisted radical prostatectomy: Comparison of selected cases by propensity score matching	Kadono Y, Nohara T, Kawaguchi S, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M, Shigehara K, Izumi K, Mizokami A.	Prostate. 2023;83(8):773-780.
Contribution of Retzius-sparing robot-assisted radical prostatectomy to the mechanism of urinary continence as demonstrated by dynamic MRI.	Kadono Y, Nohara T, Kawaguchi S, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Shigehara K, Izumi K, Yoshida K, Gabata T, Mizokami A	Sci Rep. 2023; 13(1):2902.
Comparison of the Prognostic Value of Inflammatory and Nutritional Indices in Nonmetastatic Renal Cell Carcinoma.	Makino T, Izumi K, Iwamoto H, Kadomoto S, Kadono Y, Mizokami A.	Biomedicines. 2023;11(2):533.
Sarcopenia Is Associated With Aggressive Clinicopathological Outcomes and Is a Poor Prognostic Indicator for Non-metastatic Renal Cell Carcinoma.	Makino T, Izumi K, Iwamoto H, Kadomoto S, Kadono Y, Mizokami A.	In Vivo. 2023;37(3):1304-1311.
Relation between athletic club affiliation from school age and future serum free testosterone levels in Japan: A cross-sectional study.	Kato Y, Shigehara K, Nakagawa T, Kawaguchi S, Izumi K, Kadono Y, Mizokami A.	Health Sci Rep. 2023; 6(8):e1496.
Role of Positive Biopsy Core Ratio in Prostate Cancer Patients.	Kano H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Kamijima T, Shimada T, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Kawaguchi S, Nohara T, Shigehara K, Kadono Y, Mizokami A.	Anticancer Res. 2023; 43(10):4619-4626.
The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.	Natsagdorj A, Izumi K, Hiratsuka K, Naito R, Kadomoto S, Iwamoto H, Yaegashi H, Shigehara K, Nakata H, Mizokami A.	Anticancer Res. 2023; 43(6):2561-2569.
Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study.	Kadono Y, Konaka H, Nohara T, Izumi K, Anai S, Fujimoto K, Koguchi T, Ishibashi K, Kawai N, Nakane K, Iba A, Masumori N, Takahara S, Mizokami A.	Cancers (Basel). 2023; 15(10):2745.
Combination of Sarcopenia and Hypoalbuminemia Is a Poor Prognostic Factor in Surgically Treated Nonmetastatic Renal Cell Carcinoma.	Makino T, Izumi K, Iwamoto H, Kadomoto S, Mizokami A.	Biomedicines. 2023; 11(6):1604.
Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.	Shimada T, Naito R, Toriumi R, Nakagawa R, Aoyama S, Kamijima T, Kano H, Kadomoto S, Iwamoto H, Yaegashi H, Izumi K, Kadono Y, Nakata H, Saito Y, Nakagawa-Goto K, Mizokami A.	Anticancer Res. 2023; 43(6):2561-2569.
Comparing ceftolozane/tazobactam versus piperacillin/tazobactam for the initial empiric therapy of urinary tract infections: A retrospective comparative study.	Nakagawa T, Shigehara K, Shinzawa R, Yaegashi H, Kawaguchi S, Nohara T, Izumi K, Mizokami A.	J Infect Chemother. 2023: S1341-321X(23)00205-2.

一覧に戻る